← ANALYST RATINGS · TIPRANKS
Invivyd (IVVD): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $10.00, the highest $10.00, the lowest $10.00. The average is +1,518.1% from the last price of $0.62.
Analyst ratings 4
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.65 → $0.60−7.8% | Hold | −2.8% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.66 → $0.61−7.5% | Hold | −1.8% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.63 → $0.58−7.9% | Hold | −6.1% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.63 → $0.59−7.0% | Hold | −4.7% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.63 → $0.60−5.1% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.64 → $0.59−7.4% | Hold | −4.7% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.68 → $0.65−4.1% | Hold | +5.5% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.68 → $0.66−4.0% | Hold | +6.1% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.66 → $0.63−4.0% | Hold | +1.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.66 → $0.63−4.1% | Hold | +2.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.66 → $0.63−4.0% | Hold | +1.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.66 → $0.64−4.1% | Hold | +2.9% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.73 → $0.68−6.6% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.73 → $0.68−6.7% | Hold | +10.5% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.70 → $0.66−6.7% | Hold | +6.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.71 → $0.66−6.6% | Hold | +6.8% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.70 → $0.66−6.7% | Hold | +6.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.71 → $0.66−6.6% | Hold | +7.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.71 → $0.73+3.0% | Hold | +17.8% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.71 → $0.73+3.0% | Hold | +18.4% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.68 → $0.70+2.9% | Hold | +13.8% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.69 → $0.71+3.1% | Hold | +14.4% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.68 → $0.70+2.9% | Hold | +13.8% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.69 → $0.71+2.9% | Hold | +14.9% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.73 → $0.71−3.8% | Hold | +14.4% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.74 → $0.71−3.8% | Hold | +15.0% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.71 → $0.68−3.8% | Hold | +10.5% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.71 → $0.69−3.8% | Hold | +11.0% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.71 → $0.68−3.8% | Hold | +10.5% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.72 → $0.69−3.8% | Hold | +11.7% | Reiterated | 09.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.86 → $0.73−14.4% | Hold | +18.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.86 → $0.74−14.4% | Hold | +19.6% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.83 → $0.71−14.4% | Hold | +14.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.83 → $0.71−14.4% | Hold | +15.4% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.83 → $0.71−14.4% | Hold | +14.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.84 → $0.72−14.3% | Hold | +16.0% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.98 → $0.86−12.3% | Hold | +39.0% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.99 → $0.86−13.1% | Hold | +39.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.94 → $0.83−11.4% | Hold | +34.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.94 → $0.83−11.5% | Hold | +34.8% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.95 → $0.83−13.2% | Hold | +34.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.94 → $0.84−11.1% | Hold | +35.4% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $10.00 | Buy | +1,518.1% | Reiterated | 30.09.26on TipRanks Sep 29 12:35 | −10.3%next day +2.6% · 5 days −7.1% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $10.00 | Buy | +1,518.1% | Reiterated | 29.09.26on TipRanks Sep 30 06:30 | −10.3%next day +2.6% · 5 days −7.1% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $10.00 | Buy | +1,518.1% | Reiterated | 01.09.26on TipRanks 10:50 | −7.2%next day −9.0% · 5 days −9.4% | ↗ |
| Jason Kolbert★★★★★★★★★★#12335 · hits 32% · avg −9.0% | D. Boral Capital | — | Hold | — | Downgrade | 25.11.25on TipRanks 07:45 | −6.4%next day +2.0% · 5 days −3.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Invivyd
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.00 at a price of $0.87 (+1,049.4%); now: $10.00 at $0.62 (+1,518.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 10 | 11 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.15 to $-0.11). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $15M (from $15M to $16M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Invivyd
- CEO: Marc William Elia
- Employees: 122
- 209 Church Street, New Haven, CT, 06510, US
- www.invivyd.com
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 216 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗